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Abstract
The ethical problem of the need to conduct research on the very condi-
tions that impair the ability to consent to such research is widely acknowl-
edged. People with cognitive impairment and mental illness have an
equitable right to research being conducted in areas relevant to their
treatment and care, and should be given an equitable opportunity to
participate in such research, even if they lack capacity. They also have a
right to adequate safeguards to protect their interests and respect their
wishes in regards to research participation. Provisions for involvement in
research of those who are unable to give consent have only developed
over the last 50 years. Over this period we have witnessed a proliferation
of policies, regulations and laws that govern research involving subjects
unable to give consent. There has been a parallel increase in our under-
standing of the concepts of consent and capacity, specifically as it relates to
the research context, with development of standards for research consent
and instruments to guide capacity evaluation. We review the evolution of
research governance and the underlying ethical principles that underpin
such regulations, approaches to capacity evaluation and the use of proxies
and advance research directives to facilitate research participation in
adults who lack capacity.
Introduction
It is only over the last century that we have recog-
nized that participation in research must be volun-
tary and informed. Provisions for involvement in
research of those who are unable to give consent
have only developed over the last 50 years and over
this period we have trodden a fine line between
ensuring adequate safeguards to protect the interests
of those with impaired capacity, while at the same
time ensuring research into the very conditions that
impair capacity. This paper explores the evolution of
research governance and the ethical principles that
guide such regulations, as well as approaches to
capacity evaluation and research participation in
adults who lack capacity.
Evolution of research governance
The need for informed consent for research was first
articulated in 1907 when the British Royal Commis-
sion enquired into an experiment in which subjects
signed a contract stating the purpose and risks of the
experiment, perhaps the first informed consent docu-
ment (Jonsen et al., 1998a). Subsequently, the
Nuremberg Code, in response to the perpetration of
the Nazi atrocities involving involuntary, non-
consensual human experimentation, represented the
first formal attempt to codify principles to guide
human experimentation. The Code deemed essential
the voluntary legal consent of the subject, predicated
upon an informed disclosure of the nature, duration,
purpose, method and hazards of the experiment,
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including the effects on the subject (Jonsen et al.,
1998b). Additionally the Code stipulated inclusion
of a “revocation of consent” option so that subjects
could halt participation at any time if they felt
uncomfortable.
The next major attempt to codify research gover-
nance was the promulgation of the Declaration of
Helsinki in 1964 by the World Medical Association.
Hitherto unacknowledged by the Nuremberg Code, a
provision for involvement of subjects lacking capacity
to participate in research was included in the Decla-
ration. Research was divided into two categories based
on the researcher’s intent, both categories allowing for
consent of a third party (referred to as a “legal guard-
ian”) to be substituted for that of incompetent poten-
tial participants with compromised autonomy. These
categories included:
(i) Therapeutic research – procedures primarily
aimed to benefit a particular patient but inciden-
tally also broadened knowledge of the condition
or its treatment;
(ii) Non-therapeutic research – where the intent was
to extend knowledge to benefit future patients but
made no claim to benefit individual patients
(World Medical Association, 1964).
This distinction, developed in an attempt to
protect vulnerable patients by discouraging their
involvement in non-therapeutic and theoretically
more hazardous research, has been subsequently
abandoned because of the recognition that all research
needs to be assessed according to the same criteria.
Nevertheless, the distinctive risk-benefit context of
research as opposed to treatment and the notion of a
risk hierarchy are important considerations in modern
research codes.
Over the ensuing 50 years, research regulations
have been developed in legislative frameworks and
policies of major health governing bodies to imple-
ment uniform rules on clinical trials and to protect
those who cannot give informed consent. For
example, in the USA, the President’s Commission for
the Study of Ethical Problems in Medicine and Bio-
medical and Behavioral Research published in 1982
outlined definitions of decision-making capacity as a
competent choice which required possession of a set of
values and goals, an ability to communicate and to
understand information and the ability to reason and
to deliberate about one’s choices (Kim, 2010).
The current US legislation which deals with
informed consent can be found in Title 45 of the Code
of Federal Regulations, Part 46 (Department of Health
and Human Services, 2005). The legislation has a par-
ticular emphasis on a disclosure requirement compris-
ing eight criteria, including benefits, alternatives, risks,
confidentiality, contact information and compensa-
tion, but does not include specific protection for
people unable to give consent, beyond the possibility
of obtaining permission of the impaired person’s sur-
rogate. The regulations refer to “legally authorized
representatives” (LAR) with such authority, but the
definition of who qualifies as LAR is left to the state
and local laws. Because few states have defined who
can be LAR, there remains considerable policy uncer-
tainty in the USA. There have been various attempts
in the USA, Canada and Europe to propose more
comprehensive safeguards, including recommenda-
tions for (i) capacity assessment; (ii) proxy decision-
making and respect for patient assent and dissent, and
consistency with patient interests/preferences; (iii)
institutional risk-benefit assessment and independent
monitors; and (iv) the necessity requirement (i.e. that
research must necessarily be performed on subjects
who cannot give consent) (Wendler and Prasad, 2001;
Resnick et al., 2007). However, no clear resolution or
consensus has been reached, particularly in regards to
whom such policies apply.
Similarly, in the UK, in 1991, the Medical
Research Council published guidelines for Ethical
Conduct of Research on the Mentally Incapacitated
(http://www.mrc.ac.uk/Utilities/Documentrecord/
index.htm?d=MRC002409), and guidelines for good
clinical practice in clinical trials in 1998 (Medical
Research Council, 1998). The Medicines for Human
Use (Clinical Trials) Regulations 2004 (UK) came into
force in the 2004 to cover the conduct of clinical trials
on medicinal products. The latter allowed a legal rep-
resentative of the person not connected with the
conduct of the trial to consent to the participation of
incompetent adults in medical research (Mason et al.,
2006). The Mental Capacity Act 2005 (UK), which
came into force in April 2007, governs decision-
making on behalf of adults who lack mental capacity,
both where they lose capacity at some point in their
lives, or where the incapacitating condition has been
present since birth (http://www.legislation.gov.uk/
ukpga/2005/9/contents).
Australian legislation relating to research involv-
ing those who lack capacity to consent was heralded
by the Guardianship Act 1987 (NSW), which came
into force in August 1989, well in advance of the
National Health and Medical Research Council’s
guidelines and the participation of Australian hospitals
and other medical institutions in clinical trials involv-
ing those unable to give a valid consent. This early Act
only dealt with treatments that were “experimental”
(i.e. new treatments that had not yet gained the
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support of a substantial number of medical practitio-
ners or dentists specializing in the area of practice
concerned and for which only a tribunal could give
consent), rather than clinical trials as such, which
were dealt with by subsequent legislation. Queensland
legislation authorizing the carrying out of a medical
research procedure on an incapable adult followed the
NSW Act; and Victoria, while not requiring approval
of the Tribunal, provided for a four-step process for
authorizing the carrying out of a medical research
procedure on an incapable adult. At the time of
writing, none of the other Australian states or territo-
ries have legislation dealing directly with those who
lack capacity to consent to their own treatment receiv-
ing experimental treatment or taking part in clinical
trials (O’Neill and Peisah, 2011).
Over this period the National Health and Medical
Research Council (NHMRC) published guidelines for
ethical conduct in human research, which were
updated in 2007 (NHMRC, 2007) These guidelines
emphasize the entitlement of people with a cognitive
impairment, disability or mental illness to participate
in research, and the need for care in the research
design both to take into account factors that may affect
the capacity to receive information, consent and par-
ticipate, and to make decisions about revoking
consent, and to determine if the person’s condition
makes them susceptible to discomfort or distress.
Because of the person’s vulnerability, the risks to and
burdens imposed on them by the research must be
justified by the potential benefits of the research. The
NHMRC guidelines regarding consent for people with
cognitive impairment, intellectual disability or mental
illness comprise the following:
1 Consent must be sought either from the person
themselves if they have the capacity to consent, or
the person authorized to consent on their behalf;
2 Consent should be witnessed by a person who has
the capacity to understand the merits, risks and
procedures of the research and is independent of
the research team, knows the person and is familiar
with their condition;
3 If the cognitive impairment is episodic consent
should be sought when the condition does not
interfere with the person’s capacity;
4 The process of seeking consent should include dis-
cussion of any possibility of the person losing their
capacity to consent and the person’s wishes in that
circumstance followed, unless to do so would not be
in their best interests;
5 Where consent is sought from a proxy, the
researcher should still explain to the participant as
far as possible what the research is about
6 Researchers should inform Human Research and
Ethics Committees how they propose to determine
capacity (including how the decision will be made
and by whom, criteria used and process for review-
ing capacity during the research)
7 Refusal or reluctance to participate must be
respected. Persons with diminished autonomy
cannot be made to participate against their expressed
wishes at the time (the respect for person principle).
Similarly, over the last five years there has been a
proliferation of laws, regulations and guidelines that
govern human subject research in several countries in
Asia. Clearly, we are not short on laws and regulations
guiding human research. In 2011, the Office for
Human Research Protections for the US Department
of Health and Human Services compiled the Interna-
tional Compilation of Human Research Protection, a
list of over 1,000 laws, regulations and guidelines that




A number of ethical principles have been entwined in
the various codes and legislative frameworks. These
ethical concepts are outlined below.
Beneficence
Beneficence is the requirement to consider the poten-
tial benefits (both to society in the form of increased
scientific knowledge or new treatments for future
patients, and to individual subjects in the form of
direct improvement in their health condition) arising
from a course of action and balancing these against the
potential risks or harm, and also minimizing the risk of
harms and burdens. The direct benefit to subjects is
akin to the concept of “best interests” which underlies
most surrogate decision-making. However, the
concept is both highly subjective and has variable
meanings depending on the legislative jurisdiction.
Justice
Justice refers to the need to ensure equitable distribu-
tion of resources, including health care and treatment,
and to treat all patients equally. People with cognitive
impairment and mental illness have an equitable right
to research being conducted in areas relevant to their
treatment and care, and should be given an equitable
opportunity to participate in such research, even if
C. Peisah et al. Capacity to consent to research
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they lack capacity (Katonah et al., 2009). Effective
treatment of the very conditions which potentially
impair capacity is lacking, thus creating the ethical
problem of a need for research with those who are
incapable of giving their own consent (Kim, 2010;
O’Neill and Peisah, 2011). Avoiding this dilemma by
limiting research to people who are able to decide for
themselves would deprive people who lack capacity of
proven therapies for the conditions that specifically
affect them (British Medical Association and The Law
Society, 2004).
Autonomy
Autonomy is the act of self-determination or the right
to choose, and to do so free from undue influence and
coercion. An autonomous decision is usually under-
stood as a competent decision; in the research context
this usually means that a person has the capacity to
provide informed consent to participate in research.
But sometimes facilitating the decision-making of an
incompetent person may support a degree of
autonomy. It is important to recognize that providing
support for decision-making by competent and incom-
petent patients alike can be achieved without impos-
ing one’s will and while still respecting the patient’s
right to choose. This balance between “coercion” and
“abandonment” is all the more important in the
context of our often aggressively individualistic,
Western ethical frameworks that often impose “man-
datory” autonomy (Kim, 2010).
Authenticity
Although not frequently cited as a principle, authen-
ticity is highly relevant for the context of involving
adults in research based on surrogate consent.
Authenticity is defined as the congruence between a
person’s decision and their values, including their
beliefs, commitments and relationships (Brudney,
2009). For those with neurodegenerative disorders
such as dementia, the values in question are generally
those held prior to the development of dementia or at
least prior to the development of incompetence. This is
also known as the principle of precedent autonomy
(Davis, 2002). Although in some settings incongru-
ence with previous decisions and values may signal
incompetence, authenticity should not always be seen
as a necessary component of competence as a compe-
tent person may in fact change their values and com-
mitments over time. In the research context, its
importance resides in guiding surrogate decision-
making (Brudney, 2009; Sulmasy and Snyder, 2010).
Capacity evaluation
Triggers and thresholds
The presumption of capacity is the default assumption
under Common Law. A “trigger” – usually a behavior,
diagnosis, circumstance of event may lead to a ques-
tioning of the person’s capacity at a point of time
(Attorney General’s Department of NSW, 2008). In
the research context, the decision to challenge this
presumption and assess capacity is usually made by
the research team developing the research protocol or
by the institutional ethics board, and dependent on
the research subjects or population. How and who
should assess capacity varies according to the protocol
and the rigor and degree to which procedures are
structured and specified largely depends on the risk-
benefit analysis of the research protocol, such that a
high-risk study might require an elaborate capacity
evaluation assessment scheme with a high capacity
threshold performed by independent experienced
evaluators (Kim, 2010).
Standards for research consent
The understanding of capacity to consent to research
has evolved from our understanding of the capacity to
consent to treatment, which has been derived from
American statutory and case law and scholarly
sources, and is known as “four abilities” or “four stan-
dards” model. The standards as applied to research
capacity include:
1 factual understanding of the facts or issues including
an understanding of the procedure or treatment its
risks and side effects, available options and their
advantages and disadvantages and the conse-
quences of participation and non-participation;
there may be other elements of informed consent as
dictated by the specific jurisdiction.
2 rational manipulation of information or reasoning;
3 appreciation of the nature of the situation as it
applies to the subject; and
4 evidencing or communicating a choice, preferably a
stable or consistent one (Appelbaum and Roth,
1982; Grisso & Appelbaum, 1998)
While research capacity is assessed using similar
standards to treatment consent, there are extra safe-
guards (British Medical Association and The Law
Society, 2004), with additional “facts” or “issues” that
need to be understood, reasoned and appreciated. For
example, participants involved in clinical research
should understand the difference between treatment
and research protocols, including such things as
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randomization and the use of placebos (Resnick et al.,
2007).
Instruments
The use of standard instruments to guide capacity
evaluation has been advocated for the purposes of
standardization, efficiency, ease of use by research per-
sonnel and comparison with published benchmark
data to guide capacity thresholds (Kim, 2010).
A number of instruments have been developed to
structure and standardize the assessment of capacity.
The MacArthur Competence Assessment Tool for
Clinical Research (MacCAT-CR) is probably the most
widely used instrument for the study of decision-
making capacity in research. This tool, administered
by structured interview which takes approximately
15–20 minutes to complete, comprises 21 items assess-
ing all of the four elements of capacity: understand-
ing, appreciation, reasoning and evidencing a choice
(Appelbaum & Grisso, 2001). The understanding
subscale, in particular, has been shown to have reli-
ability and predictive value in identifying patients
with mild to moderate Alzheimer’s disease who are
capable of giving consent (Karlawish et al., 2008a).
The MacCAT-CR also had predictive value in deter-
mining capacity for informed consent in schizophrenia
research (Kim et al., 2007).
Since the development of the MacCAT-CR there
have been attempts to develop more parsimonious but
still valid and reliable tests for capacity to consent to
research participation, particularly for cognitively
impaired individuals who may have limited ability to
concentrate as a result of both physical and cognitive
problems. A number of shorter tools have been devel-
oped, their brevity limiting their assessment to one or
two components of the capacity construct, and thus
their role to screening rather than capacity determi-
nation (Saks et al., 2002; Resnick et al., 2007).
Differentiating capable from incapable subjects
remains an issue, despite the aid of these standardized
tools as they yield dimension scores but not categorical
outcomes (Kim et al., 2001). The currently identified
goal of research in this area is to find markers of
potential impaired capacity. Ideally they are sensitive,
brief questionnaires targeting key aspects of disclosed
information, which effectively screen for participants
warranting more comprehensive capacity evaluations
(Palmer and Jeste, 2006). In many research centers,
the assessment of decisional capacity, particularly of
subjects with dementia, lacks uniformity, when it is
performed at all. Where decisional capacity is either
formally or informally assessed, a variety of methods
are used ranging from clinical judgment to extrapola-
tion from psychometric performance (Karlawish et al.,
2002) A study of clinicians’ perceptions of videotaped
capacity interviews involving two scenarios of differ-
ent risk (i.e. a medication-randomized clinical trial
and a neurosurgical clinical trial), showed that
although clinicians used a risk-sensitive model of
capacity determination (a higher degree of capacity
required in higher-risk situations), there is consider-
able unexplained variability in their judgments, most
likely due to variations in threshold between capacity
assessors (Kim et al., 2006; S.Y.H. Kim et al., 2011).
Capacity and diagnosis: Patient predictors
of capacity
Considerable discussion still surrounds issues related
to the capacities of patients with neuropsychiatric dis-
orders to consent to research. It is agreed, however,
that age and diagnosis – indeed any measure not spe-
cifically based on measuring functional abilities to
make decisions – should not be viewed as determi-
nants of decisional capacity (Palmer and Jeste, 2006).
The presence of disorder does not imply impairment in
capacity. Although some studies have found, for
example, that even relatively mild Alzheimer’s disease
significantly impairs consent-giving capacity (Kim
et al., 2006) there is considerable heterogeneity in
decision-making capacity even within each diagnostic
group, particularly amongst those with schizophrenia,
sufficient to warrant individualized consideration of
capacity (Jeste et al., 2006; Palmer and Jeste, 2006). Of
course, this will clearly depend on how capacity is
defined or tested, and on the complexity of the capac-
ity task. Even mild cognitive impairment (MCI) can
affect decisional capacity for complex research proto-
cols (Buckles et al., 2003; Jefferson et al., 2008).
Another important factor is the need to incorpo-
rate the overall risk-benefit profile of the research
protocol into the final categorical determinations of
capacity. Studies have shown that consultation psy-
chiatrists do follow the often-recommended (National
Bioethics Advisory Comission, 1998) guidance that as
risks increase, the threshold for competence should
increase also (Kim et al., 2006; S. Kim et al., 2011).
Individual consideration of capacity is equally
important for those with mental illnesses such as
mood disorder or schizophrenia. Although the pres-
ence of bipolar disorder appears to be a risk factor for
impaired understanding of information disclosed
under standard consent procedures, the diagnosis
should not be equated with a lack of competence to
consent (Palmer et al., 2007).
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In studies of patients with bipolar disorder and
schizophrenia, although the strongest correlates of
capacity (particularly, understanding and appreciation
of disclosed information) were cognitive test scores,
there was little evidence of differential relationships
between individual cognitive abilities on neuropsy-
chological testing and specific dimensions of capacity.
Understanding was correlated with severity of nega-
tive symptoms and of general psychopathology (Jeste
et al., 2006; Palmer et al., 2007).
Research involving adults who have
cognitive impairment
It has been suggested that as a rule of thumb, people
who lack capacity to consent for themselves should
only ever be involved in projects from which they, or
others with similar conditions are likely to benefit, and
which cannot be undertaken otherwise on people who
are able to consent (British Medical Association and the
Law Society, 2004). In two Australian states (New
South Wales and Queensland), legislation requires that
the state’s administration and guardianship tribunal
must be satisfied, before they approve of a trial involv-
ing those unable to give consent, that, having regard to
the potential benefits and risk of participation in the
trial, it is in the best interests of the patients who suffer
from the relevant condition that they take part in the
trial (see Guardianship Act, 1987 [NSW]). To meet this
criterion, the Tribunal has to be presented with some
evidence that taking part in the clinical trial will be of
benefit to the class of incapable participants them-
selves. The evidence has to go beyond the suggestion
that, if they had capacity, they would feel good about
themselves taking part in the trial.
Beyond legislative requirements of ensuring a
best interests standard, or a risk-benefit analysis, there
are number of ways of supporting the involvement of
incapacitated subjects in research. The first is by facili-
tating their own consent. The second is by considering
their previously expressed opinions as there is some
scope for including those who have made advance
directives dealing with the question of medical
research. The third is by obtaining the consent of
proxy decision-makers.
Facilitating the consent process and involvement
of cognitively impaired subjects
Decisional capacity is not necessarily an unmodifiable
trait (Jeste et al., 2003). A variety of interventions or
“remediations” can enhance understanding of
informed consent for research. Capacity may be
enhanced by providing information in an easily
understandable form. Even among individuals with
psychiatric illness or cognitive impairment, deficits in
understanding can be remedied with certain educa-
tional interventions. Deficits in patients’ understand-
ing of informed consent may be related partially to
poorly conceived, written, or organized consent mate-
rials. Effective interventions include corrected feed-
back, multiple learning trials, and more organized or
simplified consent forms (Dunn and Jeste, 2001). For
example, an interactive dialogue between patient and
investigator with clarification of key elements in the
consent form and repeated presentation of informa-
tion is likely to aid understanding of disclosed infor-
mation among patients with schizophrenia (Jeste
et al., 2003, 2006).
The wording of questions in the consent process
can affect the responses of the participant. For
example, in a study of 102 middle-aged and older
outpatients with schizophrenia or related psychotic
disorders and 20 normal comparison subjects, patients
had more difficulty than normal comparison subjects
on open-ended questions, including those asking
about study procedures, time involved, and potential
risks and benefits. Among patients, the enhanced pro-
cedure was associated with better performance on
questions about potential risks and time required than
the routine procedure. It is these “problem areas” in
the understanding of informed consent that should
be the focus of attempts to improve the consent
process for patient participants with severe mental
illness (Dunn and Jeste, 2003).
Advance research directives
There have been proposals for research regulations
and guidelines in some states of the USA and Canada
to require that research involving cognitively impaired
adults be limited to those who have completed a
formal, documented advance research directive while
competent (Wendler and Prasad, 2001; Muthappan
et al., 2005). Yet, this requirement may impede the
carrying out of important research. One study from
the USA found that only 11% of adult inpatients had
completed an advance research directive, even when
given the opportunity to do so in a clinical research
setting. Of those who completed research directives,
76% were willing to participate in research that might
help them, 49% were willing to participate in research
that would not help them and posed minimal risk, and
9% were willing to participate in research that would
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not help them and posed greater than minimal risk.
The authors suggested more flexible approaches to
protect these individuals such as:
1 developing advance directives that address both
research and clinical care;
2 requiring advance research directives for subjects at
high risk for losing the ability to consent, such as
individuals with mild Alzheimer’s disease enrolling
in longitudinal studies; and
3 developing mechanisms to allow individuals to
reject future research participation, while making
them aware that formally documenting a prefer-
ence to decline future research may preclude them
from all research including research with the poten-
tial to benefit them (Muthappan et al., 2005).
Proxy consent
Research in the UK and the USA shows that future
research involving incapacitated older patients will
need to rely heavily on proxy or substitute consent
provision (Mason et al., 2006). Again, the role of sub-
stitute decision-makers varies enormously from juris-
diction to jurisdiction in terms of who may serve as
surrogate (in Australia: “persons responsible”, guard-
ians, statutory health attorneys or, in one state doctors
when the persons responsible cannot be contacted or
ascertained), the types of research the surrogate may
consent to in terms of risk and benefits, and the
matters they must take into account before giving that
consent. Such matters include:
1 the current views of the incapable person must be
taken into consideration;
2 the past views must be taken into consideration, if
they can be ascertained; and
3 the welfare and interests of that person must be
given paramount consideration. In general, most
jurisdictions have attempted to provide some limits
on the risks borne by the subjects who are entered
into research studies via surrogate permission.
Over the last few years there has been a burgeon-
ing interest in the appointment of proxies for research
consent as alternatives to making advance research
directives (Stocking et al., 2006). It is thought that
persons suffering from neurodegenerative disorders
such as dementia may retain significant abilities,
including sufficient capacity for delegating one’s
authority for giving consent to research, even if they
are not capable of giving independent consent them-
selves (Kim and Appelbaum, 2006; Kim and Kieburtz,
2006; Kim et al., 2011).
As with any situation of proxy consent, in the
absence of an advance directive, surrogates have to
make research decisions based on informal evidence
of the person’s preferences. Yet, consent decisions of
legal representatives may not necessarily reflect those
of patients themselves and may result in under-
recruitment of patients, who if given the choice them-
selves may have chosen to participate. From 2,445
potentially eligible but incapacitated patients, proxy
consent from a relative led to trial participation of only
3.6% patients. The reasons attributed to this were that
a large number of incapacitated patients had no rela-
tive available for consent (2,286), but also 45% of
relatives approached refused to provide consent com-
pared with 18% of patients who refused to participate
in the trial. Proxy consent allowed only a small
increase in trial recruitment of incapacitated patients.
The authors suggested that the finding that more rela-
tives than patients refused to consent implies either
more caution amongst proxies than the patients them-
selves, or that proxies used different criteria when
making their decision (Mason et al., 2006). Such
caution amongst proxies may reflect a natural protec-
tive posture as well as a lack of willingness to take on
too much responsibility, a beneficent or best interests
position that provides a protective function for vulner-
able subjects who lack capacity.
Similarly, Stocking et al. (2006) interviewed 149
dyads of dementia patients and family proxies about
future enrollment in five types of research and while
they found that patients chose to cede future decision-
making to their proxies in 82.9% of the trials, patients
ceded decisions to their proxies in 80.7% of those
trials about which the dyad had given opposite
answers. Such a mismatch between patient and proxy
views regarding enrolment in research studies is more
likely to occur when proxies use a best interest rather
than a substituted judgment standard for decision-
making. Karlawish et al. (2008b) examined the views
of Alzheimer’s disease patients and their proxies at 13
research sites in the USA and found that proxies made
research enrollment decisions based on what they
thought would maximize the patient’s well-being as
opposed to a substituted judgment standard. Reasons
proxies give for participating in research include hope
of direct or indirect benefits to the patient, caregiver,
or patient’s descendants; desperation; trust in the
investigator; belief in the goodness of research; and
altruism, although these reasons vary according to the
type of research, such that in drug trials hope of direct
benefit prevails while in studies not evaluating a
potential therapy more altruistic concerns predomi-
nate (Sugarman et al., 2001).
Interestingly, there is evidence that some people
value the future role of surrogates more than their
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currently held preferences and are thus willing to cede
future decisions to participate in research that they
currently do not wish to participate in to their surro-
gates (Kim et al., 2009). Conversely, it must be recog-
nized that a sizeable minority do not wish to do so
(Stocking et al., 2006).
Conclusion
It is only since the 1960s that research policies have
made provision for involvement of subjects lacking
capacity to participate in research. However, over this
short period we have witnessed an exponential
growth internationally of policies, regulations and
laws that govern research involving subjects unable to
give consent. Shaped by fundamental ethical prin-
ciples of autonomy, justice, beneficence and authen-
ticity, as well as our growing understanding of the
concepts of consent, capacity, and surrogate decision-
making, such policies vary from jurisdiction to juris-
diction according to the different emphasis placed
on each of these constructs. Internationally, we are
not short on guidelines, but rather, we are short on
consensus.
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